Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311 ·Status: COMPLETED ·Phase: PHASE2

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

NCT02330965 ·Status: COMPLETED

BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies

NCT03269175 ·Status: COMPLETED ·Phase: PHASE4

Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis

NCT01795872 ·Status: COMPLETED ·Phase: PHASE4

Study of Diroximel Fumarate in the Real-World Setting

NCT04746976 ·Status: TERMINATED

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

NCT05576779 ·Status: COMPLETED

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144 ·Status: COMPLETED ·Phase: PHASE3

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657 ·Status: COMPLETED

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

NCT00441103 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

NCT01480076 ·Status: COMPLETED ·Phase: PHASE4

Atorvastatin in Relapsing-Remitting Multiple Sclerosis

NCT00616187 ·Status: COMPLETED ·Phase: PHASE2

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999 ·Status: COMPLETED ·Phase: PHASE2

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel

NCT04948606 ·Status: TERMINATED

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

NCT00050778 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

NCT00035529 ·Status: TERMINATED ·Phase: PHASE2

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

NCT05798520 ·Status: COMPLETED ·Phase: PHASE2

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

NCT03408093 ·Status: COMPLETED

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

NCT02410200 ·Status: COMPLETED ·Phase: PHASE2

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis

NCT02472938 ·Status: WITHDRAWN ·Phase: PHASE4

Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b

NCT00942591 ·Status: COMPLETED ·Phase: PHASE2

BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

NCT00382629 ·Status: COMPLETED ·Phase: PHASE2

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

NCT02579681 ·Status: COMPLETED ·Phase: PHASE3

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01838668 ·Status: COMPLETED ·Phase: PHASE3

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

NCT01873417 ·Status: COMPLETED ·Phase: PHASE4